Table 2.
Characteristics of ROADMAP‐OFU Population and ROADMAP Population That Did Not Participate in the OFU Study
| ROADMAP Patients Not Enrolled in OFU | ROADMAP Patients Enrolled in OFU | |||||
|---|---|---|---|---|---|---|
| Placebo (N=1338) | Olmesartan (N=1351) | Total (N=2689) | Placebo (N=877) | Olmesartan (N=881) | Total (N=1758) | |
| Mean age (y) (SD) | 57.7 (8.79) | 57.6 (9.03) | 57.7 (8.91) | 57.9 (8.35) | 57.8 (8.45) | 57.8 (8.40) |
| Male gender, n (%) | 585 (43.7) | 608 (45.0) | 1193 (44.4) | 418 (47.7) | 441 (50.1) | 859 (48.9) |
| Mean BMI (SD) | 31.0 (4.99) | 31.3 (5.00) | 31.2 (5.00) | 30.6 (4.73) | 30.9 (4.79) | 30.7 (4.76) |
| Mean duration of diabetes (months) (SD) | 70.9 (73.4) | 72.6 (73.05) | 71.8 (73.22) | 75.6 (71.0) | 75.8 (71.2) | 75.7 (71.1) |
| Metabolic syndrome, % | 1068 (79.8) | 1113 (82.4) | 2181 (81.1) | 729 (83.1) | 721 (81.8) | 1450 (82.5) |
| Anti‐diabetic drugs, n (%) | 1298 (97.0) | 1290 (95.5) | 2588 (96.2) | 825 (94.1) | 839 (95.2) | 1664 (94.7) |
| Anti‐hypertensive drugs, n (%) | 1003 (75.0) | 1018 (75.4) | 2021 (75.2) | 662 (75.5) | 656 (74.5) | 1318 (75.0) |
| Mean SBP (mm Hg) (SD) | 135.5 (14.99) | 136.4 (15.45) | 135.9 (15.23) | 136.1 (15.03) | 137.2 (15.61) | 136.7 (15.33) |
| Mean DBP (mm Hg) (SD) | 80.5 (9.46) | 80.7 (9.54) | 80.6 (9.5) | 80.1 (9.29) | 81.0 (9.81) | 80.5 (9.56) |
| Mean HbA1c (%) (SD) | 7.7 (1.72) | 7.7 (1.72) | 7.7 (1.72) | 7.6 (1.46) | 7.5 (1.43) | 7.6 (1.45) |
| Mean eGFR (mL/min per 1.73 m2) (SD) | 84.7 (17.88) | 85.1 (17.15) | 84.9 (17.51) | 84.7 (16.38) | 84.8 (16.8) | 84.8 (16.59) |
| Mean blood glucose (mmol/L) (SD) | 9.0 (3.13) | 9.0 (3.13) | 9.0 (3.13) | 9.1 (2.92) | 9.1 (2.96) | 9.1 (2.94) |
| Mean total cholesterol (mmol/L) (SD) | 5.2 (1.14) | 5.2 (1.13) | 5.2 (1.13) | 5.2 (1.11) | 5.1 (1.00) | 5.2 (1.06) |
| Mean HDL (mmol/L) (SD) | 1.2 (0.30) | 1.2 (0.29) | 1.2 (0.30) | 1.2 (0.30) | 1.2 (0.30) | 1.2 (0.30) |
| Mean LDL (mmol/L) (SD) | 3.1 (0.91) | 3.0 (0.90) | 3.0 (0.90) | 3.1 (0.89) | 3.0 (0.84) | 3.0 (0.86) |
| Mean triglyceride (mmol/L) (SD) | 2.0 (1.23) | 2.2 (1.91) | 2.1 (1.61) | 2.1 (1.34) | 2.1 (1.31) | 2.1 (1.33) |
| UACR (mg/g) (SD) | 6.0 (6.97) | 6.6 (8.34) | 6.3 (7.69) | 5.7 (6.20) | 5.9 (6.24) | 5.8 (6.22) |
| Smoker; >5 cigarettes/day (%) | 227 (17.0) | 222 (16.4) | 449 (16.7) | 139 (15.8) | 139 (15.8) | 278 (15.8) |
BMI indicates body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; OFU, observational follow up; ROADMAP, Randomized Olmesartan and Diabetes Microalbuminuria Prevention; SBP, systolic blood pressure; UACR, urinary albumin creatinine ratio.